gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 30 Jul 2015.

Insulin-like growth factor 2

Insulin-Like Growth Factor II, IGF-II, IGF2
This gene encodes a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region overlaps this gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2010] (from NCBI)
Top mentioned proteins: Insulin, Insulin-Like Growth Factor I, CAN, HAD, IGF-I receptor
Papers using Insulin-Like Growth Factor II antibodies
LYVE-1, the lymphatic system and tumor lymphangiogenesis
Lahm Harald et al., In Journal of Carcinogenesis, 2000
... Identification of PEPCK-IGF-II transgenic animals and carcinogen treatment ...
Papers on Insulin-Like Growth Factor II
Paternally Inherited IGF2 Mutation and Growth Restriction.
Eggermann et al., Tübingen, Germany. In N Engl J Med, 23 Aug 2015
In humans, mutations in IGF1 or IGF1R cause intrauterine and postnatal growth restriction; however, data on mutations in IGF2, encoding insulin-like growth factor (IGF) II, are lacking.
Placental Expression Profile of Imprinted Genes Impacts Birth Weight.
Chen et al., New York City, United States. In Epigenetics, 17 Aug 2015
[95% Confidence interval: 1.83, 7.82]), DLK1 (1.63, [1.27, 2.09]), H19 (2.79, [1.77, 4.42]), IGF2 (1.43, [1.31, 2.40]), MEG3 (1.42, [1.19, 1.71]), MEST (4.78, [2.64, 8.65]), NNAT (1.40, [1.05, 1.86]), NDN (2.52, [1.72, 3.68], PLAGL1 (1.85, [1.40, 2.44])).
Investigating the effect of excess caffeine exposure on placental angiogenesis using chicken 'functional' placental blood vessel network.
Yang et al., Guangzhou, China. In J Appl Toxicol, 14 Aug 2015
Semi-quantitative RT-PCR analysis revealed that caffeine treatment down-regulated VEGF, VEGFR2, PIGF, IGF2 and NRP1 expression, but up-regulated Ang1 and Ang2 expression.
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
Domingo-Domenech et al., New York City, United States. In Cancer Cell, Mar 2015
Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggressive properties regulated by GATA2.
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Gessler et al., Würzburg, Germany. In Cancer Cell, Mar 2015
Recurrent mutations included a hotspot mutation (Q177R) in the homeo-domain of SIX1 and SIX2 in tumors with high proliferative potential (18.1% of blastemal cases); mutations in the DROSHA/DGCR8 microprocessor genes (18.2% of blastemal cases); mutations in DICER1 and DIS3L2; and alterations in IGF2, MYCN, and TP53, the latter being strongly associated with dismal outcome.
Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2.
Balk et al., Seattle, United States. In Cancer Cell, Mar 2015
In this issue of Cancer Cell, Vidal and colleagues identify increased GATA2 and its AR-independent transactivation of IGF2 as a mechanism that can mediate taxane resistance through activation of IGF1/insulin receptor signaling.
Portrait of the PI3K/AKT pathway in colorectal cancer.
Lothe et al., Oslo, Norway. In Biochim Biophys Acta, Jan 2015
In colorectal cancer the most commonly observed pathway changes are IGF2 overexpression, PIK3CA mutations and PTEN mutations and deletions.
Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies.
Tomblin et al., Huntington, United States. In Front Endocrinol (lausanne), Dec 2014
Molecular targeting therapies that have been used in solid tumors include anti-IGF1R antibodies, anti-IGF1/IGF2 antibodies, and small molecule inhibitors that suppress IGF1R and IR kinase activity.
Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.
Tacke et al., Aachen, Germany. In Hepatobiliary Surg Nutr, Dec 2014
HSC, the main collagen-producing cells during fibrosis, are currently targeted using nanoconstructs that recognize the mannose 6-phosphate and insulin-like growth factor II, peroxisome proliferator activated receptor 1, platelet-derived growth factor (PDGF) receptor β, or integrins.
Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors.
Ragazzon et al., Paris, France. In Front Endocrinol (lausanne), Dec 2014
Most ACAs are associated with abnormalities of the cAMP signaling pathway, whereas most ACCs are linked to alterations in IGF2, TP53, or the Wnt/βcatenin pathways.
Analysis artefacts of the INS-IGF2 fusion transcript.
Madsen et al., Denmark. In Bmc Mol Biol, Dec 2014
We here exemplify this by an in-depth analysis of the INS-IGF2 fusion transcript, which has recently been reported to be among the highest expressed transcripts in human pancreatic beta cells and its protein indicated as a novel autoantigen in Type 1 Diabetes.
Ligand-Binding Affinity at the Insulin Receptor Isoform-A and Subsequent IR-A Tyrosine Phosphorylation Kinetics are Important Determinants of Mitogenic Biological Outcomes.
Forbes et al., Adelaide, Australia. In Front Endocrinol (lausanne), Dec 2014
The IR-A not only binds insulin but also insulin-like growth factor-II (IGF-II) with high affinity.
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.
Kuo et al., Stanford, United States. In Nat Med, Jul 2014
Colon organoid culture functionally validated the microRNA miR-483 as a dominant driver oncogene at the IGF2 (insulin-like growth factor-2) 11p15.5 CRC amplicon, inducing dysplasia in vitro and tumorigenicity in vivo.
IGF-IR Targeted Therapy: Past, Present and Future.
Varewijck et al., Rotterdam, Netherlands. In Front Endocrinol (lausanne), 2013
Activation of the IR-A by insulin-like growth factor-II (IGF-II) bypasses the IGF-IR and its inhibition.
Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.
Hammer et al., Ann Arbor, United States. In Am J Pathol, 2012
With the combination of stabilized beta-catenin and elevated Igf2 expression, adrenal glands were larger, displayed earlier onset of hyperplasia, and developed more frequent macroscopic adenomas.
Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites.
Millikan et al., Chapel Hill, United States. In Cancer Causes Control, 2012
Data indicate an inverse association between the insulin-like growth factor-2 (IGF-II) Apa1 A-variant and colon cancer risk (OR = 0.49, 95 % CI 0.28-0.88) in Whites only.
Akt1 and insulin-like growth factor 2 (Igf2) regulate placentation and fetal/postnatal development.
Soares et al., Kansas City, United States. In Int J Dev Biol, 2011
Data show that both Akt1-/- and Igf2-/- mice exhibited decreased placental weight, fetal weight and viability.
Prenatal famine and genetic variation are independently and additively associated with DNA methylation at regulatory loci within IGF2/H19.
Lumey et al., Leiden, Netherlands. In Plos One, 2011
Prenatal famine and genetic variation showed similar associations with IGF2/H19 methylation and their contributions were additive
Methylation defect in imprinted genes detected in patients with an Albright's hereditary osteodystrophy like phenotype and platelet Gs hypofunction.
Freson et al., Leuven, Belgium. In Plos One, 2011
significant IGF2 hypermethylation (20 +/- 10 vs. 14 +/- 7%; p<0.05) and SNURF hypomethylation (23 +/- 6 vs. 32 6%; p<0.001) was found in Albright's hereditary osteodystrophy patients vs. controls.
share on facebooktweetadd +1mail to friends